Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.
about
Clinical development of nintedanib for advanced non-small-cell lung cancerA comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patientsRole of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinomaAssociation of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol.Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung CancerPrognostic Significance of Modified Advanced Lung Cancer Inflammation Index (ALI) in Patients with Small Cell Lung Cancer_ Comparison with Original ALI.Body Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review.Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinibSarcopenia Does Not Affect Survival or Outcomes in Soft-Tissue Sarcoma.Sarcopenia and chemotherapy-mediated toxicityClinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.Sarcopenia in solid organ transplantation.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.The adverse effects of sorafenib in patients with advanced cancers.Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.Cachexia: clinical features when inflammation drives malnutrition.Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients.Cachexia in patients with oesophageal cancer.A review of body composition and pharmacokinetics in oncology.Impact of sarcopenia in the management of urological cancer patients.The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.Clinical Implications of Sarcopenic Obesity in Cancer.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.Nutrition and Aging: a Practicing Oncologist's Perspective.Impact of sarcopenia on surgical site infection after restorative proctocolectomy for ulcerative colitis.Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study.A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one.Muscle wasting associated with the long-term use of mTOR inhibitors.Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.Sorafenib in thyroid cancer patients: learning from toxicity.Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract.Low skeletal muscle is associated with toxicity in patients included in phase I trials.Computed tomography diagnosed cachexia and sarcopenia in 725 oncology patients: is nutritional screening capturing hidden malnutrition?Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.
P2860
Q26775822-00AB596B-E1E8-49DB-8FE9-FAE885CAFC38Q28364947-8A83A6A7-704E-45C9-A7FD-30B4E909F469Q33418378-EEC921AF-3A0F-473F-BA0E-7CD54EEF0F8BQ33435839-34E54052-CE9F-43D7-A2F0-E6881E01283CQ35708619-C1E3050C-F406-440D-8369-DDA7E239F55AQ35799268-03EED076-5CFF-43BD-A090-3E05896D4ACEQ35915754-C5DF29AB-00B4-44A2-89DA-381CFE48E244Q36153929-B00184AF-56D0-4AFD-94CE-66F89F3963AEQ36154581-47B77812-CCEF-4343-A1C0-0C2D94366400Q36349363-DD27A9ED-5C12-4CB4-95E9-501E34BA0EE3Q36369039-D30A792F-1CD7-4DFC-9BE2-6C9DAC656C4BQ37572738-8A3207A1-5FC3-465D-9758-5EADD4CE6C10Q38176985-7337451B-1D5C-4FCC-BED5-DC6FB9676E7BQ38188425-143F21F7-F242-419D-805C-CBF49EE6EF5EQ38201503-B90D60B2-F997-436C-91CC-754598A060FFQ38286308-9CDDAB3A-0EBE-422C-8AB5-9334391F87A3Q38391227-A48641ED-3DC4-4687-952B-880D01643828Q38391442-94A07FE1-BE99-4717-9F78-75952FB8661AQ38633201-FF36E3B9-8D9B-47CD-B943-A9586350CD10Q38634739-CF57368F-1953-48FF-972D-F8AB17E7869EQ38709340-D1CA639C-3F69-4972-ADF8-CB9DF0CFC227Q38749004-9D37FDF9-4416-47DB-ACDE-70AC483CBFA7Q38842194-11E9AD24-666B-4B0F-8FE3-1C7B45AA4472Q38931979-6D580F9F-436B-40DE-9FA9-BDC9F6BE23B0Q38936104-5A11F1DA-1B19-4545-8CA0-450CA436A893Q39648893-52003DC2-BC24-4B97-98B0-AA353F2037E9Q40213114-CB1431DA-8ECE-42EC-B580-145FE2DEEF40Q40387345-087A70DA-88BE-4D4C-98E4-CB030ED8A25FQ40503715-2E2010DE-7260-4B59-A95B-60AAE066AED2Q40648141-F6E640DF-9F79-47C6-B235-2F6E724DD76FQ40648872-A77D5E16-DE97-4B0E-A6DA-26D31B2DD2B9Q41470871-2E6338B4-B1F3-4251-BFEE-3494D212D6A7Q41896035-10142C7D-6B2C-413D-ABE4-EFCFA6C38C03Q42324302-9C9FF336-EC9D-45B7-8860-7CA71C9461B5Q42364404-40D55F24-9C99-43F7-A7CB-87ACBD215D38Q42770685-0AB34B2F-8F68-49A2-AC20-4172DF01C841Q45938278-7E375089-5666-43F1-97D9-5A65A232513AQ46520115-661C1FBC-3E4B-4390-A79A-61EAEC4FC1B9Q47260860-BE12D2D0-2790-4445-8708-53A0C24AA3F7Q47797910-2E3CC2ED-1C70-4785-A8D6-8F18222ED3B1
P2860
Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Sarcopenia and body mass index ...... ties in renal cancer patients.
@en
type
label
Sarcopenia and body mass index ...... ties in renal cancer patients.
@en
prefLabel
Sarcopenia and body mass index ...... ties in renal cancer patients.
@en
P2093
P2860
P356
P1476
Sarcopenia and body mass index ...... ties in renal cancer patients.
@en
P2093
C Tlemsani
F Goldwasser
M Peyromaure
N Barry Delongchamps
O Huillard
P Boudou-Rouquette
P2860
P2888
P304
P356
10.1038/BJC.2013.58
P407
P577
2013-03-05T00:00:00Z
P5875
P6179
1000012185